MedTrace Logo

Trial of Enteral Glutamine on Intestinal Permeability in Critically Ill Patients

NCT03113240 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-04-10

No results posted yet for this study

Summary

Glutamine-induced recovery in intestinal barrier function by reducing bacterial translocation was demonstrated in previous studies. In this trial, intensive care unit patients with enteral feeding will receive either enteral glutamine or maltodextrin as placebo for 10 days and the effects of the intervention on intestinal permeability will be assessed.

Conditions

  • Critical Illness
  • Enteral Nutrition
  • Intestinal Permeability

Interventions

DRUG

Glutamin

Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.

OTHER

Maltodextrin

Maltodextrin mixed with water given via NG tube q 4 hours.

Sponsors & Collaborators

  • Shahid Beheshti University

    lead OTHER

Principal Investigators

  • Zahra Vahdat Shariatpanahi, MD, PhD · Faculty of Nutrition and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2017-10-01
Completion
2017-10-01

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03113240 on ClinicalTrials.gov